Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.49 |
| ▸ | CDK9 | P50750 | 3/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CCNH | P51946 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998978 | 0.90 | SYK (0.59) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5999180 | 0.81 | SYK (0.49) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6852913 | 0.80 | SYK (0.48) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5732836 | 0.78 | SYK (0.61) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5998636 | 0.77 | SMN1; SMN2 (0.57) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4903303 | 0.77 | ABL1 (0.66) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| Water SCHEMBL7817247 | 0.77 | SYK (0.59) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL1927060 | 0.76 | ABL1 (0.80) | SYKNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL27741349 | 0.75 | CDK2 (0.74) | CDK2CDK1CCNT1CCNA2CDK9 | |
| SCHEMBL19347450 | 0.74 | SYK (1.00) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151096-B2 | Cyclic compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-12-19 | — | — | US | disclosed |
| US-20040235841-A1 | Cyclic compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2004-11-25 | — | — | US | disclosed |
| WO-2004078682-A2 | CYCLIC COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235841-A1 | Cyclic compounds and compositions as protein kinase inhibitors | CDK2, CDK5, CDK1 | SYK 2923/4885NPC1 3486/4885RAB9A 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.